Toilets at food and petrol stops in poor state
A RECENT study has revealed that about 80% of toilets at food outlets and petrol stations across Malaysia are dirty, foul-smelling and poorly maintained.
The survey, conducted by the National Consumer Foundation of Malaysia (YPNM), inspected more than 2,000 toilets at eateries and petrol stations, including those in Sabah and Sarawak, Utusan Malaysia reported.
According to the survey, many of these facilities lacked basic hygiene necessities such as soap, adequate water supply and essential cleaning equipment.
YPNM president Datuk Dr Mohd Firdaus Abdullah said toilet cleanliness reflects not only the people's mindset but also the nation's image.
'Cleanliness of public toilets is a vital aspect of our culture and national identity.
'Unfortunately, many food business operators still treat this issue as trivial,' said Mohd Firdaus.
The foundation's findings highlight an urgent need for stricter enforcement and greater awareness regarding hygiene standards, especially in high-traffic public facilities.
> Kosmo! reported on a mother's tireless journey of love and sacrifice in raising her special needs son, who has been bedridden since he was a baby.
Zuriana Daud's eldest son Muhammad Aiman, now 17, suffers from physical disabilities that require full-time care.
She said he drinks special formula milk, wears disposable diapers and needs round-the-clock attention.
'He's easy to care for. When I look at his face, I feel strong. He's a blessing, not a burden,' said Zuriana.
The above articles are compiled from the vernacular newspapers (Bahasa Malaysia, Chinese and Tamil dailies). As such, stories are grouped according to the respective language/medium. Where a paragraph begins with a, it denotes a separate news item.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
17 hours ago
- Malaysian Reserve
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING, July 3, 2025 /PRNewswire/ — Brii Biosciences Limited ('Brii Bio,' stock code: a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced that it has entered into a license and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd ('Joincare Group'). Joincare Group will obtain an exclusive license from Brii Bio for the research, development, and commercialization of BRII-693 in the Greater China region. Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval and commercialization of BRII-693 in Greater China. In return, Brii Bio has received an upfront payment and will receive additional development and commercial milestone payments upon certain future milestone events plus tiered royalties on net product sales. BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with multidrug- and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections, particularly those caused by carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) and Enterobacterales (CRE). Discovered through iterative structural modifications of the polymyxin scaffold, BRII-693 was designed to enhance antibacterial potency while reducing the toxicity commonly associated with older polymyxin agents such as renal and neuro-toxicities. In phase 1 studies, BRII-693 demonstrated a favorable safety, tolerability, and PK profile in healthy non-Chinese and Chinese participants. Brii Bio received IND approval from CDE of NMPA for a Phase 1 PK bridging study in China supporting a future Phase 3 registrational trial in patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio, commented: 'The growing threat of antimicrobial resistance in Greater China underscores the urgency for novel hospital antibiotics. With Joincare Group's proven capabilities in manufacturing and commercializing hospital antibiotics, we found the ideal partner to accelerate the development and commercialization of BRII-693. This partnership enables us to deliver a critical care medicine to Chinese patients facing life threatening infections.' Mr. Nanqi Lin, Chief Executive Officer of Joincare Group, stated, 'The Company has a long-standing track record of excellence in innovative drug research and development, underpinned by deep scientific expertise and a robust R&D platform. Driven by Brii Bio's well-established R&D system, the BRII-693 project demonstrated strong innovation and scientific rigor. Early data showing encouraging results in terms of therapeutic potential, pharmacodynamics, and pharmacokinetics, suggesting BRII-693's high potential to become a best-in-class therapy to address the critical unmet clinical needs. We are confident in the clinical prospects of BRII-693. This collaboration further strengthened Joincare Group's strategic positioning in the anti-infection disease area. We look forward to launching this asset soon, providing patients with more high-quality treatment options.' About BRII-693 BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with MDR/XDR gram-negative bacterial infections, especially carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Brii Bio holds exclusive global rights to develop and commercialize BRII-693. About Brii Bio Brii Biosciences Limited ('Brii Bio', stock code: is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit About Joincare Group Established in 1992, Joincare Group (Joincare Pharmaceutical Group Industry Co., Ltd) is an innovative scientific research-based integrated pharmaceutical group after many years of steady operation and rapid development. The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries. The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms, and has carried out rich pipeline layouts around respiratory, anti-infective, gastrointestinal, assisted reproduction, psychiatric, oncology and other areas of significant clinical needs, forming a rich and diversified product matrix and pipeline of drugs under development. Forward-looking Statements This contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
The Star
2 days ago
- The Star
How does long-term exercise slow ageing? Chinese scientists have an answer
A team of Chinese scientists has found that betaine – a compound naturally occurring in the kidneys during long-term exercise – can slow down the ageing process. By looking at the key molecular pathways that help to reshape the physiology of the human body and delay ageing through exercise, they revealed that betaine acts as a core messenger in this process. It prevents inflammation and the ageing of multiple organs by targeting and inhibiting an enzyme called TBK1. The findings not only shed light on the mechanism behind the anti-ageing effects of exercise, but also suggest possible anti-ageing strategies by simulating exercise, according to the joint team from the Chinese Academy of Sciences' Institute of Zoology and Beijing Institute of Genomics. Led by Liu Guanghui and Qu Jing from the zoology institute and Zhang Weiqi from the genomics institute, the researchers reported their findings in the peer-reviewed journal Cell on June 25. Nutrition, exercise, sleep and stress management are widely considered the four pillars of health, including by institutions such as the World Health Organization. Much research has shown that exercise can powerfully influence the ageing process. However, the Chinese researchers noted the fundamental molecular mechanisms between exercise and longevity remained poorly understood, as did other questions such as how various exercise patterns differed in their beneficial effects on health. To solve this puzzle, they launched a study in 2019 to investigate the effects of exercise on health in both mice and humans. By 2023, they had made progress, having systematically analysed the cellular and molecular responses of 14 organ tissues to long-term aerobic exercise in young and aged mice. Building on these findings, the researchers continued their study with human participants. In this phase, 13 healthy male volunteers were recruited. The participants were required to run 5km (3.1 miles) in 40 minutes and then take up long-term regular exercise for 25 days. After that, the researchers collected blood and faecal samples from the participants at various intervals, as well as health examination data. They later used a range of analytical methods, including plasma proteomics analysis, to study the samples and establish a research framework. The six-year research project identified the kidney as 'the key responsive organ' for exercise and found that betaine, its product of metabolism, serves as the core molecular messenger for slowing ageing. Even more significant for real-life applications, the team discovered that supplementing this compound 'can precisely mimic the benefits of long-term exercise', according to the authors. In experiments on aged mice, the team found that oral administration of betaine could extend their healthy lifespan, significantly improving functional indicators such as metabolic capacity, kidney function and motor coordination, while also reducing depressive-like behaviour and improving cognitive function. The team pointed out that betaine's efficacy at low doses and its good safety profile 'offer a potential anti-ageing strategy for the elderly', who are unable to undertake long-term intense exercise. Furthermore, they said the study pioneered a new research paradigm capable of 'translating complex physiological effects into quantifiable, actionable chemical language', opening up a new avenue for future ageing intervention studies. - SOUTH CHINA MORNING POST
The Star
2 days ago
- The Star
2,000-year-old steel acupuncture needles unearthed in China's Jiangxi province
BEIJING: Archaeologists in China have uncovered the country's earliest known steel acupuncture needles, a remarkable medical find buried for over two millennia in the tomb of the Marquis of Haihun in East China's Jiangxi province, according to the provincial cultural relics and archaeological institute. Steel acupuncture needles inside a jade tube discovered in the famed tomb of the Marquis of Haihun in Nanchang, Jiangxi province. - China Daily/ANN "At least five needle-like objects were visible in the tube's cross-section," said Yang Jun, leader of the excavation team at the Marquis of Haihun's tomb in Jiangxi. The delicate needles date back over 2,000 years. They were discovered in a jade tube inside a gold-foiled lacquer box and were crafted with steelworking techniques far ahead of their time. Centuries underground have left them corroded and broken, requiring careful analysis to confirm their purpose. Steel needles and a jade tube discovered in the famed tomb of the Marquis of Haihun. - China Daily/ANN Each needle measures 0.3 to 0.5mm in diameter. Yang noted that they were likely wrapped in cloth prior to being placed in the jade tube, a practice that ensured hygiene and safe handling. Gu Man, an expert from the China Academy of Chinese Medical Sciences, said the needles are believed to be the earliest steel medical acupuncture needles discovered in China to date, serving as crucial evidence for the history of steel metallurgy and ancient Chinese medicine during the Western Han Dynasty (206 BC-AD 24). - China Daily/ANN
